Royality Med Pharmaceuticals Group (RMPG) builds on over a decade of pioneering research at the intersection of human stem cell biology and physics. As a research-driven company, RMPG is dedicated to discovering innovative drugs and therapies for genetic diseases. We’ve developed a cutting-edge, human organoid-based platform for agnostic drug discovery — uniquely scalable to high-throughput screening.
Founded in 1997, RMPG was established to advance our global leadership in researching and developing a portfolio of patented molecules with novel mechanisms of action that precisely target biological pathways involved in the diseases we aim to treat.